Skip to main content

Table 16 Assessment of responsiveness of the EQ-5D-3L and the EQ-5D-5L measures to changes in the VAS, for the subgroup in Belgium

From: Measurement properties of EQ-5D-3L and EQ-5D-5L in recording self-reported health status in older patients with substantial multimorbidity and polypharmacy

 

EQ-5D-3L at 6 months (mean)

EQ-5D-3L at 12 months (mean)

Difference between 12 and 6 months EQ-5D-3L (95% CI)

Effect size (Cohen’s D)a

n

% reporting 3L score increase

3L-VAS

      

 Improved

0.82

0.84

0.02 (− 0.05 to 0.09)

0.25

6

33

 No change

0.80

0.77

− 0.02 (− 0.11 to 0.06)

− 0.12

32

25

 Worsened

0.80

0.77

− 0.02 (0.10 to 0.04)

− 0.13

20

20

 

EQ-5D-5L at 6 months (mean)

EQ-5D-5L at 12 months (mean)

Difference between 12 and 6 months EQ-5D-5L (95% CI)

Effect size (Cohen’s D)

n

% reporting 5L score increase

5L-VAS

 Improved

0.70

0.70

0.00 (− 0.15 to 0.15)

− 0.01

9

33

 No change

0.80

0.78

− 0.02 (− 0.07 to 0.01)

− 0.17

29

41

 Worsened

0.78

0.74

− 0.03 (− 0.12 to 0.05)

− 0.18

20

30

  1. aCohen’s D effect sizes of between 0.2 and 0.5 are considered small, 0.5 and 0.8 moderate and > 0.8 large